World's Best Scientists 2026 revealed!
Markus Peck-Radosavljevic

Markus Peck-Radosavljevic

D-Index & Metrics

Medicine

D-Index
92
Citations
29390
World Ranking
11362
National Ranking
59

Overview

Markus Peck-Radosavljevic is affiliated with the Medical University of Vienna in Austria. Their research focuses primarily on medicine, with a notable concentration in hepatology. Subfields of study include hepatology, epidemiology, oncology, surgery, and pulmonary and respiratory medicine.

Their work addresses several main topics, such as:

  • Liver Disease Diagnosis and Treatment
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Liver Disease and Transplantation
  • Pancreatic and Hepatic Oncology Research
  • Hepatitis C virus research
  • Pancreatitis Pathology and Treatment
  • Hepatitis B Virus Studies

Markus Peck-Radosavljevic has collaborated frequently with several co-authors, including:

  • Simona Bota
  • M Razpotnik
  • G Essler
  • J Weber-Eibel
  • Florian Hucke

Their publications have appeared in various venues, notably:

  • Zeitschrift für Gastroenterologie
  • Journal für Gastroenterologische und Hepatologische Erkrankungen
  • Endoscopy
  • Journal of Hepatology
  • Liver International

Recent papers by Markus Peck-Radosavljevic include:

  • "NASH limits anti-tumour surveillance in immunotherapy-treated HCC," 2021, Nature
  • "Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial," 2023, The Lancet
  • "Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score," 2021, Journal of Hepatology
  • "Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups," 2020, Gut
  • "Systemic Therapy of Advanced Hepatocellular Carcinoma," 2020, Future Oncology

Best Publications

  • The burden of liver disease in Europe. A review of available epidemiological data.

    Martin Blachier;Henri Leleu;Markus Peck-Radosavljevic;Dominique Charles Valla

  • NASH limits anti-tumour surveillance in immunotherapy-treated HCC

    Dominik Pfister;Dominik Pfister;Nicolás Gonzalo Núñez;Roser Pinyol;Olivier Govaere

  • Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

    Andrew X. Zhu;Masatoshi Kudo;Eric Assenat;Stéphane Cattan

  • Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

    Michael Manns;Didier Samuel;Edward J Gane;David Mutimer

  • Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis.

    Simona Bota;Harald Herkner;Ioan Sporea;Petra Salzl

  • Hepatocyte IKKβ/NF-κB Inhibits Tumor Promotion and Progression by Preventing Oxidative Stress-Driven STAT3 Activation

    Guobin He;Guann Yi Yu;Vladislav Temkin;Hisanobu Ogata

  • Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis.

    Mattias Mandorfer;Simona Bota;Philipp Schwabl;Theresa Bucsics

  • Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt

    B Angermayr;M Cejna;F Karnel;M Gschwantler

  • The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma

    Wolfgang Sieghart;Florian Hucke;Matthias Pinter;Ivo Graziadei

  • Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol

    Thomas Reiberger;Gregor Ulbrich;Arnulf Ferlitsch;Berit Anna Payer

  • Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.

    Thomas Reiberger;Arnulf Ferlitsch;Berit A. Payer;Mattias Mandorfer

  • An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis.

    Angelo Luca;Angelo Luca;Berhard Angermayr;Guido Bertolini;Franz Koenig

  • Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension

    Mattias Mandorfer;Karin Kozbial;Philipp Schwabl;Clarissa Freissmuth

  • Platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study.

    Edoardo G Giannini;Atif Zaman;Anna Kreil;Annarosa Floreani

  • Transarterial chemoembolization: modalities, indication, and patient selection

    Wolfgang Sieghart;Florian Hucke;Markus Peck-Radosavljevic

  • Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

    Lorenza Rimassa;Eric Assenat;Markus Peck-Radosavljevic;Marc Pracht

  • Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.

    Jens Ricke;Heinz Josef Klümpen;Holger Amthauer;Irene Bargellini

  • Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy.

    Wolfgang Sieghart;Doris Losert;Sabine Strommer;Daniel Cejka

  • Cancer and liver cirrhosis: implications on prognosis and management

    Matthias Pinter;Michael Trauner;Markus Peck-Radosavljevic;Wolfgang Sieghart

  • Report Title: The burden of liver disease in Europe: a review of available epidemiological data

    Martin Blachier;Henri Leleu;Markus Peck-Radosavljevic;Charles Valla

Frequent Co-Authors

Thomas Reiberger
Thomas Reiberger Medical University of Vienna
Michael Trauner
Michael Trauner Medical University of Vienna
Peter Ferenci
Peter Ferenci Medical University of Vienna
Masatoshi Kudo
Masatoshi Kudo Kindai University
Jonel Trebicka
Jonel Trebicka University Hospital of Münster
Christoph Sarrazin
Christoph Sarrazin Goethe University Frankfurt
Fabio Piscaglia
Fabio Piscaglia University of Bologna
Johannes Lammer
Johannes Lammer Medical University of Vienna
Jean-Luc Raoul
Jean-Luc Raoul Institut de Cancérologie de l'Ouest (ICO)
Ulrich Spengler
Ulrich Spengler University of Bonn

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Medicine is a dynamic field, and professionals often pursue related degrees to broaden their expertise or advance their careers. Numerous accredited online programs now offer flexible learning opportunities for students and healthcare professionals. For those interested in preventive medicine and wellness, earning a nutrition bachelor degree online can provide critical knowledge about diet and its impact on health.

Healthcare professionals seeking leadership roles may benefit from cahme-accredited online mha programs, which focus on healthcare administration and management. Registered nurses looking to enhance their qualifications can enroll in online rn to bsn programs without clinical requirements, offering a streamlined path for professional advancement.

Additionally, those aiming for the highest level of nursing practice may consider dnp online programs to achieve a Doctor of Nursing Practice degree. Each of these online pathways can complement or extend a traditional medical education, opening doors to a variety of rewarding roles in healthcare.

Best Scientists Citing Markus Peck-Radosavljevic

Trending Scientists

Recently Published Articles